Aze Wilson1,2,3, Wendy A Teft1, Bridget L Morse1, Yun-Hee Choi4, Sarah Woolsey3, Marianne K DeGorter1, Robert A Hegele5, Rommel G Tirona1,3, Richard B Kim6. 1. Division of Clinical Pharmacology, Department of Medicine, Western University, 339 Windermere Road B9-130, London, ON, N6A 5A5, Canada. 2. Division of Gastroenterology, Department of Medicine, Western University, 339 Windermere Road, London, ON, N6A 5A5, Canada. 3. Department of Physiology and Pharmacology, Western University, Medical Sciences Building, Rm 216, London, ON, N6A 5C1, Canada. 4. Department of Epidemiology and Biostatistics, Western University, Kresge Building, Rm K201, London, ON, N6A 5C1, Canada. 5. Division of Endocrinology, Department of Medicine, Western University, 339 Windermere Road, London, ON, N6A 5A5, Canada. 6. Division of Clinical Pharmacology, Department of Medicine, Western University, 339 Windermere Road B9-130, London, ON, N6A 5A5, Canada. Richard.Kim@lhsc.on.ca.
Abstract
BACKGROUND: The gastrointestinal (GI) microbiome is recognized for potential clinical relevance in inflammatory bowel disease (IBD). Data suggest that there is a disease-dependent loss of microbial diversity in IBD. Trimethylamine-N-oxide (TMAO) is generated by GI anaerobes through the digestion of dietary phosphatidylcholine and carnitine in a microbial-mammalian co-metabolic pathway. IBD-related changes in the gut microbiome may result in disease-specific changes in TMAO plasma concentrations. AIM: To determine whether TMAO plasma levels in IBD are altered compared to controls and whether they correlate with disease presence or activity. METHODS: Liquid chromatography-tandem mass spectrometry was used to measure TMAO, choline, and carnitine plasma levels in 479 subjects (373 non-IBD controls, 106 IBD). Subjects were also genotyped for the flavin monooxygenase (FMO)3 variants, E158K and E308G. RESULTS: Plasma TMAO levels were 2.27 µM lower in the IBD population compared to the control population (p = 0.0001). Lower TMAO levels were similarly seen in active ulcerative colitis (UC) (1.56 µM) versus inactive disease (3.40 µM) (p = 0.002). No difference was seen in active Crohn's disease (CD) versus inactive CD. No intergroup variation existed in plasma TMAO levels based on FMO3 genotype. Choline levels were higher in IBD, while carnitine levels were similar between the two groups, suggesting that lower TMAO levels in IBD were not due to dietary differences. CONCLUSIONS: Decreased TMAO levels are seen in IBD compared to a non-IBD population. These data suggest that TMAO may have potential as a biomarker to support IBD diagnosis as well as to assess disease activity in UC.
BACKGROUND: The gastrointestinal (GI) microbiome is recognized for potential clinical relevance in inflammatory bowel disease (IBD). Data suggest that there is a disease-dependent loss of microbial diversity in IBD. Trimethylamine-N-oxide (TMAO) is generated by GI anaerobes through the digestion of dietary phosphatidylcholine and carnitine in a microbial-mammalian co-metabolic pathway. IBD-related changes in the gut microbiome may result in disease-specific changes in TMAO plasma concentrations. AIM: To determine whether TMAO plasma levels in IBD are altered compared to controls and whether they correlate with disease presence or activity. METHODS: Liquid chromatography-tandem mass spectrometry was used to measure TMAO, choline, and carnitine plasma levels in 479 subjects (373 non-IBD controls, 106 IBD). Subjects were also genotyped for the flavin monooxygenase (FMO)3 variants, E158K and E308G. RESULTS: Plasma TMAO levels were 2.27 µM lower in the IBD population compared to the control population (p = 0.0001). Lower TMAO levels were similarly seen in active ulcerative colitis (UC) (1.56 µM) versus inactive disease (3.40 µM) (p = 0.002). No difference was seen in active Crohn's disease (CD) versus inactive CD. No intergroup variation existed in plasma TMAO levels based on FMO3 genotype. Choline levels were higher in IBD, while carnitine levels were similar between the two groups, suggesting that lower TMAO levels in IBD were not due to dietary differences. CONCLUSIONS: Decreased TMAO levels are seen in IBD compared to a non-IBD population. These data suggest that TMAO may have potential as a biomarker to support IBD diagnosis as well as to assess disease activity in UC.
Authors: Ben P Willing; Johan Dicksved; Jonas Halfvarson; Anders F Andersson; Marianna Lucio; Zongli Zheng; Gunnar Järnerot; Curt Tysk; Janet K Jansson; Lars Engstrand Journal: Gastroenterology Date: 2010-10-08 Impact factor: 22.682
Authors: Xiaojiao Zheng; Guoxiang Xie; Aihua Zhao; Linjing Zhao; Chun Yao; Norman H L Chiu; Zhanxiang Zhou; Yuqian Bao; Weiping Jia; Jeremy K Nicholson; Wei Jia Journal: J Proteome Res Date: 2011-10-24 Impact factor: 4.466
Authors: Carolyn A Miller; Karen D Corbin; Kerry-Ann da Costa; Shucha Zhang; Xueqing Zhao; Joseph A Galanko; Tondra Blevins; Brian J Bennett; Annalouise O'Connor; Steven H Zeisel Journal: Am J Clin Nutr Date: 2014-06-18 Impact factor: 7.045
Authors: Zeneng Wang; Bruce S Levison; Jennie E Hazen; Lillian Donahue; Xin-Min Li; Stanley L Hazen Journal: Anal Biochem Date: 2014-04-01 Impact factor: 3.365
Authors: Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis Journal: Science Date: 2011-09-01 Impact factor: 47.728
Authors: Xochitl C Morgan; Timothy L Tickle; Harry Sokol; Dirk Gevers; Kathryn L Devaney; Doyle V Ward; Joshua A Reyes; Samir A Shah; Neal LeLeiko; Scott B Snapper; Athos Bousvaros; Joshua Korzenik; Bruce E Sands; Ramnik J Xavier; Curtis Huttenhower Journal: Genome Biol Date: 2012-04-16 Impact factor: 13.583
Authors: Maria Laura Santoru; Cristina Piras; Antonio Murgia; Vanessa Palmas; Tania Camboni; Sonia Liggi; Ivan Ibba; Maria Antonia Lai; Sandro Orrù; Sylvain Blois; Anna Lisa Loizedda; Julian Leether Griffin; Paolo Usai; Pierluigi Caboni; Luigi Atzori; Aldo Manzin Journal: Sci Rep Date: 2017-08-25 Impact factor: 4.379